Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Deoxyephedrine
2. Desoxyephedrine
3. Desoxyn
4. Hydrochloride, Methamphetamine
5. Madrine
6. Metamfetamine
7. Methamphetamine
8. Methylamphetamine
9. N Methylamphetamine
10. N-methylamphetamine
1. 51-57-0
2. Methamphetamine Hcl
3. (+)-methamphetamine Hydrochloride
4. Adipex
5. Dexoval
6. S-(+)-methamphetamine Hydrochloride
7. Methamphetaminium Chloride
8. Tonedron
9. D-methaphetamine Hydrochloride
10. Deofed
11. Isophen
12. Desoxyn
13. Methylisomyn
14. Soxysympamine
15. Chestox
16. Desepin
17. Desodex
18. Desoxyfed
19. Desoxyne
20. Dexstim
21. Doxyfed
22. Drinalfa
23. Efroxine
24. Eufodrinal
25. Gerovit
26. Madrine
27. Pervitin
28. Syndrox
29. Destim
30. Dextim
31. Dosoxy
32. Hyphet
33. Meth
34. Obedrin-la
35. Desoxo-5
36. Metamfetamine Hydrochloride
37. Norodin Hydrochloride
38. (+)-n,alpha-dimethylphenethylamine Hydrochloride
39. Methylamphetamine Hydrochloride
40. (+)methamphetamine Hydrochloride
41. Des-o-e
42. D-desoxyephedrine Hydrochloride
43. Dee Dex 10
44. Methedrine Hydrochloride
45. Methaphetaminium Chloride
46. Semoxydrine Hydrochloride
47. Dee -5
48. Methamphetamine Hydrochloride Cii
49. Chebi:35340
50. Metamphetamine Hydrochloride
51. Dee -10
52. 997f43z9cv
53. D-o-e
54. Desoxyephedrine Hydrochloride
55. (+)-methamphetamine Chloride
56. D-methamphetamine Hydrochloride
57. Nsc-169505
58. N-methylamphetamine Hydrochloride
59. Philopon
60. Benzeneethanamine, N,alpha-dimethyl-, Hydrochloride, (alphas)-
61. (+)-methylamphetamine Hydrochloride
62. Isophen (van)
63. L-methamphetamine Hydrochloride
64. (2s)-n-methyl-1-phenylpropan-2-amine;hydrochloride
65. Gerobit
66. (+)-2-methylamino-2-phenylpropane Hydrochloride
67. D-methylamphetamine Hydrochloride
68. Levmetamfetamine Hydrochloride
69. (+)-l-methamphetamine Hydrochloride
70. Einecs 200-106-9
71. Nsc 169505
72. Wq4872m3c8
73. L-desoxyephedrine Hydrochloride
74. Unii-997f43z9cv
75. Ai3-20155
76. D-n,alpha-dimethylphenethylamine Hydrochloride
77. (s)-(+)-methamphetamine Hydrochloride
78. D-n-methyl-beta-phenylisopropylamine Hydrochloride
79. Desoxyn (tn)
80. Einecs 212-552-1
81. L-methamphetamine Hcl
82. Phenethylamine, N,alpha-dimethyl-, Hydrochloride, (+)-
83. Benzeneethanamine, N,alpha-dimethyl-, Hydrochloride, (s)-
84. Methamphetamine Hydrochloride [usp:jan]
85. (+)-methamphetamine Hydrochloride Solution
86. Ncgc00247704-01
87. Dsstox_cid_28790
88. Dsstox_rid_83059
89. Dsstox_gsid_48864
90. L-n-methyl-beta-phenylisopropylamine Hydrochloride
91. Methylamfetamine Hydrochloride
92. Schembl42100
93. N,alpha-dimethylphenethylamine Hydrochloride, (-)-
94. Unii-wq4872m3c8
95. (2s)-n-methyl-1-phenylpropan-2-amine Hydrochloride
96. (+)-(s)-n,alpha-dimethylphenethylamine Hydrochloride
97. Methamphetamine Hydrogen Chloride
98. Chembl1200952
99. Dtxsid8048864
100. Phenethylamine, N,alpha-dimethyl-, Hydrochloride, (-)-
101. Phenethylamine, N,alpha-dimethyl-, Hydrochloride, (s)-(+)-
102. Tox21_112856
103. Cas-51-57-0
104. Methamphetamine Hydrochloride (jp17/usp)
105. Methamphetamine Hydrochloride [mi]
106. Metamfetamine Hydrochloride [mart.]
107. Methamphetamine Hydrochloride [jan]
108. Metamfetamine Hydrochloride [who-dd]
109. Methamphetamine Hydrochloride [vandf]
110. D02242
111. Methamphetamine Hydrochloride [orange Book]
112. Methamphetamine Hydrochloride Cii [usp-rs]
113. Methamphetamine Hydrochloride [usp Monograph]
114. Methyl-[(2s)-1-phenylpropan-2-yl]azanium;chloride
115. Q27116464
116. (+)-(s)-n,.alpha.-dimethylphenethylamine Hydrochloride
117. Benzeneethanamine, N,.alpha.-dimethyl-, Hydrochloride, (s)-
118. Benzeneethanamine, N,alpha-dimethyl-, Hydrochloride (1:1), (alphas)-
119. Methamphetamine Hydrochloride ((s)-(+)-methamphetamine Hydrochloride)
120. Methamphetamine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
121. (+)-methamphetamine Hydrochloride Solution, Analytical Standard, For Drug Analysis, 1.0 Mg/ml In Methanol
122. Methamphetamine Hydrochloride ((s)-(+)-methamphetamine Hydrochloride) 0.1 Mg/ml In Methanol (as Free Base)
123. Methamphetamine Hydrochloride ((s)-(+)-methamphetamine Hydrochloride) 1.0 Mg/ml In Methanol (as Free Base)
Molecular Weight | 185.69 g/mol |
---|---|
Molecular Formula | C10H16ClN |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 3 |
Exact Mass | 185.0971272 g/mol |
Monoisotopic Mass | 185.0971272 g/mol |
Topological Polar Surface Area | 12 Ų |
Heavy Atom Count | 12 |
Formal Charge | 0 |
Complexity | 95 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | DESOXYN |
Active Ingredient | METHAMPHETAMINE HYDROCHLORIDE |
Company | RECORDATI RARE (Application Number: N005378) |
2 of 2 | |
---|---|
Drug Name | METHAMPHETAMINE HYDROCHLORIDE |
Active Ingredient | METHAMPHETAMINE HYDROCHLORIDE |
Company | MAYNE PHARMA INC (Application Number: A091189); WEST-WARD PHARMS INT (Application Number: A203846) |
Dopamine Agents
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
Adrenergic Agents
Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Details:
The MDMA-LSD trial, the first-ever to combine both drugs, is scheduled to start in the fourth quarter in Basel, Switzerland. Combined MDMA-LSD treatments have the potential to create next-generation psychedelic-assisted therapy paradigms.
Lead Product(s): Methamphetamine Hydrochloride,LSD
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Lead Product(s) : Methamphetamine Hydrochloride,LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mind Med Announces First-Ever Clinical Trial Combining MDMA and LSD
Details : The MDMA-LSD trial, the first-ever to combine both drugs, is scheduled to start in the fourth quarter in Basel, Switzerland. Combined MDMA-LSD treatments have the potential to create next-generation psychedelic-assisted therapy paradigms.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2020
Details:
EmpathBio, a wholly-owned subsidiary of ATAI Life Sciences is developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.
Lead Product(s): Methamphetamine Hydrochloride
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Lead Product(s) : Methamphetamine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EmpathBio, a wholly-owned subsidiary of ATAI Life Sciences is developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2020
Details:
MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a component of these therapies.
Lead Product(s): Methamphetamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: Mind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 27, 2020
Lead Product(s) : Methamphetamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Mind Medicine
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
Details : MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a component of these therapies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 27, 2020
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Excipient Details : ACTILLETS™ are microcrystalline cellulose spheres used in advanced drug formulations as starter cores for drug layering and coating.
Pharmacopoeia Ref : NA
Technical Specs : Bulk density: 0.80
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Dosage Form : Orodispersible Tablet
Grade : Oral
Application : Chewable & Orodispersible Aids
Excipient Details : CS90 is a directly compressible calcium carbonate with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-175, Tapped Density: 0.85
Ingredient(s) : Calcium Carbonate Excipient
Dosage Form : Orodispersible Tablet
Grade : Oral
Application : Chewable & Orodispersible Aids
Excipient Details : MS90 is a directly compressible magnesium hydroxide with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-170, Taped Density: 0.80
Ingredient(s) : Starch
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?